Human OGT/HINCUT-1/HRNT1 ORF/cDNA clone-Adeno-associate virus(AAV) plasmid (NM_181672.2)

Cat. No.: pGMAAV000104
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human OGT/HINCUT-1/HRNT1 Adeno-associated virus expression plasmid (ITR-vector) for OGT AAV packaging, OGT AAV production.The purified Human OGT/HINCUT-1/HRNT1 AAV particle serves as an invaluable asset for in-depth in vivo OGT studies, mechanism of action (MOA) research, and the evolution of OGT-associated gene therapy strategies.

Our GM-AAV ITR vector is optimized with the G-NEXT™ multi-serotypes AAV vector system. Explore the G-NEXT™ system in detail.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to OGT/HINCUT-1 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMAAV000104
Gene Name OGT
Accession Number NM_181672.2
Gene ID 8473
Species Human
Product Type Adeno-associate virus(AAV) plasmid (overexpression)
Insert Length 3141 bp
Gene Alias HINCUT-1,HRNT1,MRX106,O-GLCNAC,OGT1
Fluorescent Reporter Null
Mammalian Cell Selection Null
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGGCGTCTTCCGTGGGCAACGTGGCCGACAGCACAGAACCAACGAAACGTATGCTTTCCTTCCAAGGGTTAGCTGAGTTGGCACATCGAGAATATCAGGCAGGAGATTTTGAGGCAGCTGAGAGACACTGCATGCAGCTCTGGAGACAAGAGCCAGACAATACTGGTGTGCTTTTATTACTTTCATCTATACACTTCCAGTGTCGAAGGCTGGACAGATCTGCTCACTTTAGCACTCTGGCAATTAAACAGAACCCCCTTCTGGCAGAAGCTTATTCGAATTTGGGGAATGTGTACAAGGAAAGAGGGCAGTTGCAGGAGGCAATTGAGCATTATCGACATGCATTGCGTCTCAAACCTGATTTCATCGATGGTTATATTAACCTGGCAGCCGCCTTGGTAGCAGCGGGTGACATGGAAGGGGCAGTACAAGCTTACGTCTCTGCTCTTCAGTACAATCCTGATTTGTACTGTGTTCGCAGTGACCTGGGGAACCTGCTCAAAGCCCTGGGTCGCTTGGAAGAAGCCAAGGCATGTTATTTGAAAGCAATTGAGACGCAACCGAACTTTGCAGTAGCTTGGAGTAATCTTGGCTGTGTTTTCAATGCACAAGGGGAAATTTGGCTTGCAATTCATCACTTTGAAAAGGCTGTCACCCTTGACCCAAACTTTCTGGATGCTTATATCAATTTAGGAAATGTCTTGAAAGAGGCACGCATTTTTGACAGAGCTGTGGCAGCTTATCTTCGTGCCCTAAGTTTGAGTCCAAATCACGCAGTGGTGCACGGCAACCTGGCTTGTGTATACTATGAGCAAGGCCTGATAGATCTGGCAATAGACACCTACAGGCGGGCTATCGAACTACAACCACATTTCCCTGATGCTTACTGCAACCTAGCCAATGCTCTCAAAGAGAAGGGCAGTGTTGCTGAAGCAGAAGATTGTTATAATACAGCTCTCCGTCTGTGTCCCACCCATGCAGACTCTCTGAATAACCTAGCCAATATCAAACGAGAACAGGGAAACATTGAAGAGGCAGTTCGCTTGTATCGTAAAGCATTAGAAGTCTTCCCAGAGTTTGCTGCTGCCCATTCAAATTTAGCAAGTGTACTGCAGCAGCAGGGAAAACTGCAGGAAGCTCTGATGCATTATAAGGAGGCTATTCGAATCAGTCCTACCTTTGCTGATGCCTACTCTAATATGGGAAACACTCTAAAGGAGATGCAGGATGTTCAGGGAGCCTTGCAGTGTTATACGCGTGCCATCCAAATTAATCCTGCATTTGCAGATGCACATAGCAATCTGGCTTCCATTCATAAGGATTCAGGGAATATTCCAGAAGCCATAGCTTCTTACCGCACGGCTCTGAAACTTAAGCCTGATTTTCCTGATGCTTATTGTAACTTGGCTCATTGCCTGCAGATTGTCTGTGATTGGACAGACTATGATGAGCGAATGAAGAAGTTGGTCAGTATTGTGGCTGACCAGTTAGAGAAGAATAGGTTGCCTTCTGTGCATCCTCATCATAGTATGCTATATCCTCTTTCTCATGGCTTCAGGAAGGCTATTGCTGAGAGGCACGGCAACCTGTGCTTAGATAAGATTAATGTTCTTCATAAACCACCATATGAACATCCAAAAGACTTGAAGCTCAGTGATGGTCGGCTGCGTGTAGGATATGTGAGTTCCGACTTTGGGAATCATCCTACTTCTCACCTTATGCAGTCTATTCCAGGCATGCACAATCCTGATAAATTTGAGGTGTTCTGTTATGCCCTGAGCCCAGACGATGGCACAAACTTCCGAGTGAAGGTGATGGCAGAAGCCAATCATTTCATTGATCTTTCTCAGATTCCATGCAATGGAAAAGCAGCTGATCGCATCCATCAGGATGGAATTCATATCCTTGTAAATATGAATGGCTATACTAAGGGCGCTCGAAATGAGCTTTTTGCTCTCAGGCCAGCTCCTATTCAGGCAATGTGGCTGGGATACCCTGGGACGAGTGGTGCGCTTTTCATGGATTATATTATCACTGATCAGGAAACTTCGCCAGCTGAAGTTGCTGAGCAGTATTCCGAGAAATTGGCTTATATGCCCCACACTTTTTTTATTGGTGATCATGCTAATATGTTCCCTCACCTGAAGAAAAAAGCAGTCATCGATTTTAAGTCCAATGGGCACATTTATGACAATCGGATAGTTCTGAATGGCATCGACCTCAAAGCATTTCTTGATAGTCTACCAGATGTGAAAATTGTCAAGATGAAGTGTCCTGATGGAGGAGACAATGCAGATAGCAGTAACACAGCTCTTAATATGCCTGTTATTCCTATGAATACTATTGCAGAAGCAGTTATTGAAATGATTAACCGAGGACAGATTCAAATAACAATTAATGGATTCAGTATTAGCAATGGACTGGCAACTACTCAGATCAACAATAAGGCTGCAACTGGAGAGGAGGTTCCCCGTACCATTATTGTAACCACCCGTTCTCAGTACGGGTTACCAGAAGATGCCATCGTATACTGTAACTTTAATCAGTTGTATAAAATTGACCCTTCTACTTTGCAGATGTGGGCAAACATTCTGAAGCGTGTTCCCAATAGTGTACTCTGGCTGTTGCGTTTTCCAGCAGTAGGAGAACCTAATATTCAACAGTATGCACAAAACATGGGCCTGCCCCAGAACCGTATCATTTTTTCACCTGTTGCTCCTAAAGAGGAACACGTCAGGAGAGGCCAGCTGGCTGATGTCTGCTTGGACACTCCACTCTGTAATGGGCACACCACAGGGATGGATGTCCTCTGGGCAGGGACCCCCATGGTGACTATGCCAGGAGAGACTCTTGCTTCTCGAGTTGCAGCATCCCAGCTCACTTGCTTAGGTTGTCTTGAGCTTATTGCTAAAAACAGACAAGAATATGAAGACATAGCTGTGAAGCTGGGAACTGATCTAGAATACCTGAAGAAAGTTCGTGGCAAAGTCTGGAAGCAAAGAATATCTAGCCCTCTGTTCAACACCAAACAATACACAATGGAACTAGAGCGGCTCTATCTACAGATGTGGGAGCATTATGCAGCTGGCAACAAACCTGACCACATGATTAAGCCTGTTGAAGTCACTGAGTCAGCATAA
ORF Protein Sequence MASSVGNVADSTEPTKRMLSFQGLAELAHREYQAGDFEAAERHCMQLWRQEPDNTGVLLLLSSIHFQCRRLDRSAHFSTLAIKQNPLLAEAYSNLGNVYKERGQLQEAIEHYRHALRLKPDFIDGYINLAAALVAAGDMEGAVQAYVSALQYNPDLYCVRSDLGNLLKALGRLEEAKACYLKAIETQPNFAVAWSNLGCVFNAQGEIWLAIHHFEKAVTLDPNFLDAYINLGNVLKEARIFDRAVAAYLRALSLSPNHAVVHGNLACVYYEQGLIDLAIDTYRRAIELQPHFPDAYCNLANALKEKGSVAEAEDCYNTALRLCPTHADSLNNLANIKREQGNIEEAVRLYRKALEVFPEFAAAHSNLASVLQQQGKLQEALMHYKEAIRISPTFADAYSNMGNTLKEMQDVQGALQCYTRAIQINPAFADAHSNLASIHKDSGNIPEAIASYRTALKLKPDFPDAYCNLAHCLQIVCDWTDYDERMKKLVSIVADQLEKNRLPSVHPHHSMLYPLSHGFRKAIAERHGNLCLDKINVLHKPPYEHPKDLKLSDGRLRVGYVSSDFGNHPTSHLMQSIPGMHNPDKFEVFCYALSPDDGTNFRVKVMAEANHFIDLSQIPCNGKAADRIHQDGIHILVNMNGYTKGARNELFALRPAPIQAMWLGYPGTSGALFMDYIITDQETSPAEVAEQYSEKLAYMPHTFFIGDHANMFPHLKKKAVIDFKSNGHIYDNRIVLNGIDLKAFLDSLPDVKIVKMKCPDGGDNADSSNTALNMPVIPMNTIAEAVIEMINRGQIQITINGFSISNGLATTQINNKAATGEEVPRTIIVTTRSQYGLPEDAIVYCNFNQLYKIDPSTLQMWANILKRVPNSVLWLLRFPAVGEPNIQQYAQNMGLPQNRIIFSPVAPKEEHVRRGQLADVCLDTPLCNGHTTGMDVLWAGTPMVTMPGETLASRVAASQLTCLGCLELIAKNRQEYEDIAVKLGTDLEYLKKVRGKVWKQRISSPLFNTKQYTMELERLYLQMWEHYAAGNKPDHMIKPVEVTESA

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-MP2223-Ab Anti-OGT1/ OGT/ HINCUT-1 monoclonal antibody
    Target Antigen GM-Tg-g-MP2223-Ag OGT VLP (virus-like particle)
    ORF Viral Vector pGMLV001746 Human OGT Lentivirus plasmid
    ORF Viral Vector pGMAD000506 Human OGT Adenovirus plasmid
    ORF Viral Vector pGMAD000681 Human OGT Adenovirus plasmid
    ORF Viral Vector pGMAD001640 Human OGT Adenovirus plasmid
    ORF Viral Vector pGMAAV000104 Human OGT Adeno-associate virus(AAV) plasmid
    ORF Viral Vector pGMPC001483 Human OGT Mammalian (Non-Viral Vector) plasmid
    ORF Viral Vector pGMPC001755 Human OGT Mammalian (Non-Viral Vector) plasmid
    ORF Viral Vector vGMLV001746 Human OGT Lentivirus particle
    ORF Viral Vector vGMAD000506 Human OGT Adenovirus particle
    ORF Viral Vector vGMAD000681 Human OGT Adenovirus particle
    ORF Viral Vector vGMAD001640 Human OGT Adenovirus particle
    ORF Viral Vector vGMAAV000104 Human OGT Adeno-associate virus(AAV) particle


    Target information

    Target ID GM-MP2223
    Target Name OGT
    Gene Group Identifier
    （Target Gene ID in Homo species)         		8473
    Gene ID 100056148 (Equus caballus), 101094162 (Felis catus), 108155 (Mus musculus), 26295 (Rattus norvegicus)
    480955 (Canis lupus familiaris), 532053 (Bos taurus), 698268 (Macaca mulatta), 8473 (Homo sapiens)
    Gene Symbols & Synonyms OGT,Ogt,Ogtl,1110038P24Rik,4831420N21Rik,OGT1,HRNT1,MRX106,XLID106,HINCUT-1,O-GLCNAC
    Target Alternative Names 1110038P24Rik,4831420N21Rik,HINCUT-1,HRNT1,MRX106,O-GLCNAC,O-GlcNAc transferase subunit p110,O-linked N-acetylglucosamine transferase 110 kDa subunit (OGT),OGT,OGT1,Ogt,Ogtl,UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit,XLID106
    Uniprot Accession O15294,P56558,Q8CGY8
    Additional SwissProt Accessions: Q8CGY8,P56558,O15294
    Uniprot Entry Name
    Protein Sub-location Transmembrane Protein
    Category
    Disease Prostate Cancer
    Disease from KEGG Insulin resistance, Other types of O-glycan biosynthesis
    Gene Ensembl ENSECAG00000023721, ENSMUSG00000034160, ENSCAFG00845018937, ENSBTAG00000000902, ENSMMUG00000015238, ENSG00000147162
    Target Classification


    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.